Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosisGlobeNewsWire • 03/25/25
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)PRNewsWire • 03/20/25
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)GlobeNewsWire • 03/20/25
Novartis Reports Updated Positive Data From Phase III SMA ProgramZacks Investment Research • 03/20/25
Circulating DNA RNA Patent Landscape Report and Forecast 2024-2032: Nantomics, Genentech, and Novartis are Pivotal in the Development of the $16.4 Billion MarketGlobeNewsWire • 03/14/25
Novartis Pharmaceuticals and Folia Health Partner on Innovative App-Based Study to Assess Real-World Experience of IgA NephropathyGlobeNewsWire • 03/13/25
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2025 Annual General MeetingGlobeNewsWire • 03/07/25
10 Dividend Aristocrat Bargains To Help You SWAN During This Trade War TurmoilSeeking Alpha • 03/06/25
Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)PRNewsWire • 02/28/25
Novartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G)GlobeNewsWire • 02/28/25
Syngenta acquires genetic repository from Novartis to boost biologic crop protectionReuters • 02/26/25